
Opinion|Videos|October 16, 2024
Comorbidities and Complications Associated With Friedreich Ataxia
Author(s)Sub Subramony, M.D.
Key Takeaways
- Cardiac complications like arrhythmias, heart failure, and myocardial infarction significantly impact mortality rates in patients with comorbidities.
- The interaction between cardiac issues and comorbidities such as diabetes and hypertension complicates patient management.
Sub Subramony, M.D., discusses the most prevalent complications and comorbidities in Friedreich ataxia, emphasizing the frequent cardiac complications and their significant impact on mortality rates.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What are the most prevalent complications and comorbidities, and specifically, what cardiac complications are frequently encountered and how do they factor into mortality rates?
Advertisement
Related to this article

The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.

Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.

Cleveland roundtable panelists across 4 disease states name access, not evidence, as the shared barrier to care.

Alice Hall-Partyka, JD, a partner at Crowell & Moring explains the lawsuits challenging CMS' Medicaid rule on pediatric gender care and its legal weak points.

Siva Mohan, MD, explains how drug costs drive silent nonadherence, PA burden, and biosimilar hesitancy, and what payers can do about it.

Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
Medicaid Obesity GLP-1 Coverage May Offset Some Diabetes-Labeled Use
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5



